As of October 2021, more than 225,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 450,000 patient years1
>7,000 patients in clinical trials and open-label extension
>220,000 patients with post-marketing experience
As of October 2021, more than 225,000 patients with RMS and PPMS have started ocrelizumab globally, amounting to a total of more than 450,000 patient years1
>7,000 patients in clinical trials and open-label extension
>220,000 patients with post-marketing experience
References
1. Roche data on file: 31 October 2021, post-marketing experience; 30 November 2020, clinical trials data cut-off